AR060362A1 - Agente para prevenir / tratar el cancer - Google Patents

Agente para prevenir / tratar el cancer

Info

Publication number
AR060362A1
AR060362A1 ARP070101453A ARP070101453A AR060362A1 AR 060362 A1 AR060362 A1 AR 060362A1 AR P070101453 A ARP070101453 A AR P070101453A AR P070101453 A ARP070101453 A AR P070101453A AR 060362 A1 AR060362 A1 AR 060362A1
Authority
AR
Argentina
Prior art keywords
agent
prevent
treat cancer
seq
amino acid
Prior art date
Application number
ARP070101453A
Other languages
English (en)
Inventor
S Sato
T Oshima
T Kurokawa
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Priority to CA002666249A priority Critical patent/CA2666249A1/en
Priority to KR1020097009036A priority patent/KR20090078339A/ko
Priority to US12/444,382 priority patent/US20100008928A1/en
Priority to PCT/JP2007/069908 priority patent/WO2008044754A1/ja
Priority to MX2009003126A priority patent/MX2009003126A/es
Priority to EP07829644A priority patent/EP2067791A4/en
Priority to AU2007307536A priority patent/AU2007307536A1/en
Priority to CNA2007800371476A priority patent/CN101541834A/zh
Priority to PE2007001348A priority patent/PE20081456A1/es
Priority to RU2009117237/10A priority patent/RU2009117237A/ru
Priority to JP2008538759A priority patent/JPWO2008044754A1/ja
Priority to BRPI0717024-6A2A priority patent/BRPI0717024A2/pt
Priority to CL200702879A priority patent/CL2007002879A1/es
Publication of AR060362A1 publication Critical patent/AR060362A1/es
Priority to IL197389A priority patent/IL197389A0/en
Priority to TN2009000090A priority patent/TN2009000090A1/fr
Priority to CR10676A priority patent/CR10676A/es
Priority to EC2009009276A priority patent/ECSP099276A/es
Priority to MA31823A priority patent/MA30816B1/fr
Priority to CO09044621A priority patent/CO6190538A2/es
Priority to NO20091783A priority patent/NO20091783L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Un anticuerpo monoclonal humano contra una proteína que comprende la misma o sustancialmente la misma secuencia de aminoácidos que la secuencia de aminoácidos representada por la SEC ID N°:1 o SEC ID N°: 3, su péptido parcial o una sal del mismo, es util como agente para prevenir/tratar el cáncer, etc., un inductor de apoptosis de células cancerosas, un inhibidor del crecimiento de células cancerosas, un agente citotoxico contra células cancerosas a través de un mecanismo de defensa del huésped mediado por la region FC de un anticuerpo y demás.
ARP070101453A 2005-10-07 2007-04-04 Agente para prevenir / tratar el cancer AR060362A1 (es)

Priority Applications (20)

Application Number Priority Date Filing Date Title
RU2009117237/10A RU2009117237A (ru) 2006-10-06 2007-10-04 Средство для профилактики/лечения рака
BRPI0717024-6A2A BRPI0717024A2 (pt) 2006-10-06 2007-10-04 Anticorpo, célula de hibridoma, agente de diagnótico, medicamento, métodos para prevenir/tratar câncer, para induzir apoptose células cancerosas , para inibir crescimento de células cancerosas e para destruir células cancerosas, uso de um anicorpo monoclonal e agente para prevenir ou tratar câncer de mama.
JP2008538759A JPWO2008044754A1 (ja) 2006-10-06 2007-10-04 癌の予防・治療剤
PCT/JP2007/069908 WO2008044754A1 (fr) 2006-10-06 2007-10-04 Agent prophylactique ou thérapeutique pour le cancer
KR1020097009036A KR20090078339A (ko) 2006-10-06 2007-10-04 암의 예방·치료제
EP07829644A EP2067791A4 (en) 2006-10-06 2007-10-04 PROPHYLACTIC OR THERAPEUTIC AGENT FOR CANCER
AU2007307536A AU2007307536A1 (en) 2006-10-06 2007-10-04 Agent for preventing/treating cancer
CNA2007800371476A CN101541834A (zh) 2006-10-06 2007-10-04 癌症的预防和/或治疗剂
PE2007001348A PE20081456A1 (es) 2006-10-06 2007-10-04 Anticuerpo monoclonal contra nectina 2
CA002666249A CA2666249A1 (en) 2006-10-06 2007-10-04 Agent for preventing/treating cancer
US12/444,382 US20100008928A1 (en) 2006-10-06 2007-10-04 Agent for preventing/treating cancer
MX2009003126A MX2009003126A (es) 2006-10-06 2007-10-04 Agente para prevenir/tratar el cancer.
CL200702879A CL2007002879A1 (es) 2007-04-04 2007-10-05 Anticuerpo monoclonal contra nectina-2; celula de hibridoma que lo produce; composicion farmaceutica que lo comprende; y su uso para tratar cancer.
IL197389A IL197389A0 (en) 2006-10-06 2009-03-03 Prophylactic or therapeutic agent for cancer
TN2009000090A TN2009000090A1 (en) 2007-04-04 2009-03-16 Prophylactic or therapeutic agent for canger
CR10676A CR10676A (es) 2006-10-06 2009-03-20 Agente para prevenir/ tratar el cancer
EC2009009276A ECSP099276A (es) 2006-10-06 2009-04-23 Agente para prevenir/tratar el cancer
MA31823A MA30816B1 (fr) 2006-10-06 2009-04-27 Agent prophylactique ou therapeutique pour le cancer
CO09044621A CO6190538A2 (es) 2006-10-06 2009-05-04 Agente para prevenir/tratar el cancer
NO20091783A NO20091783L (no) 2006-10-06 2009-05-05 Middel for a forebygge/behandle kreft

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005295146 2005-10-07
PCT/JP2006/320429 WO2007043635A1 (ja) 2005-10-07 2006-10-06 癌の予防・治療剤

Publications (1)

Publication Number Publication Date
AR060362A1 true AR060362A1 (es) 2008-06-11

Family

ID=37942856

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070101453A AR060362A1 (es) 2005-10-07 2007-04-04 Agente para prevenir / tratar el cancer

Country Status (9)

Country Link
US (1) US20090142346A1 (es)
EP (1) EP1932857A1 (es)
JP (1) JPWO2007043635A1 (es)
AR (1) AR060362A1 (es)
CA (1) CA2639119A1 (es)
CL (1) CL2007000974A1 (es)
PE (1) PE20080909A1 (es)
TW (1) TW200840825A (es)
WO (1) WO2007043635A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2663334A4 (en) * 2011-01-10 2016-01-13 Univ Emory ANTIBODIES AGAINST INFLUENZA
JP6656677B2 (ja) * 2016-09-23 2020-03-04 ティーエフケイ株式会社 化合物又はその塩、抗炎症剤、肺がんに対する抗がん剤、化合物又はその塩の製造方法、炎症性疾患の治療方法及び肺がんの治療方法
EP3548071A4 (en) 2016-11-30 2020-07-15 OncoMed Pharmaceuticals, Inc. METHOD FOR TREATING CANCER WITH TIGIT-BINDING ACTIVE SUBSTANCES

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030129685A1 (en) * 1998-10-28 2003-07-10 Jian Ni 12 human secreted proteins
AU1305302A (en) * 2000-10-05 2002-04-15 Immunex Corp Nectin polypeptides, polynucleotides, methods of making and use thereof
EP1733743A4 (en) * 2004-04-09 2007-06-27 Takeda Pharmaceutical PREVENTIVE / REMEDY AGAINST CANCER

Also Published As

Publication number Publication date
EP1932857A1 (en) 2008-06-18
US20090142346A1 (en) 2009-06-04
JPWO2007043635A1 (ja) 2009-04-16
CA2639119A1 (en) 2007-04-19
CL2007000974A1 (es) 2008-05-02
TW200840825A (en) 2008-10-16
PE20080909A1 (es) 2008-08-28
WO2007043635A1 (ja) 2007-04-19

Similar Documents

Publication Publication Date Title
AR063153A1 (es) Anticuerpo monoclonal para prevenir/tratar el cancer
ES2606173T3 (es) Composición farmacéutica para el tratamiento y/o la prevención del cáncer
ES2675375T3 (es) Anticuerpos monoclonales contra claudina 18 para el tratamiento del cáncer
ES2531083T3 (es) Formulaciones estables de polipéptidos y usos de las mismas
RU2008136324A (ru) Желудочно-кишечный пролиферативный фактор и его применения
PE20110310A1 (es) Axmi-115, axmi-113, axmi-005, axmi-163 y axmi-184: proteinas insecticidas
MX2010002716A (es) Uso de slit, nefrina, efrina o semaforina para el tratamiento de enfermedades de cartilago.
CL2012000063A1 (es) Polipéptido factor ix (fix) o un fragmento del mismo porque comprende la modificación de un aminoácido; vector; célula; método para expresar el polipéptido fix; composición farmacéutica; uso de la composición para tratar enfermedades trombóticas, hemorrágicas y coagulación intravascular diseminada (cid) (div. sol. 1796-07).
MX2011010908A (es) Anticuerpos anti-tnf-alfa y sus usos.
AR066338A1 (es) Proteinas toxinas activas contra hemipteros y coleopteros de bacillus thuringiensis
CO6180466A2 (es) Composiciones y metodos para diagnosticar y tratar cancer
NO20063026L (no) Antistoffer
AR077096A1 (es) Toxinas cry insecticidas dig-11 de bacillus thuringiensis
MX2011006685A (es) Inhibidores de metaloproteinas de matriz de membrana tipo-1 y sus usos.
AR073237A1 (es) Proteinas de bacillus thuringiensis que son toxinas activas contra hemipteros y coleopteros
PE20140190A1 (es) Moduladores de proteinas notum y metodos de uso
NO20082510L (no) En fremgangsmate for konsentrasjon av et polypeptid
PE20181054A1 (es) Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion
RS52537B (en) ACTIVIN-ACTRII ANTAGONISTS AND USES FOR ANEMIA TREATMENT
AR067980A1 (es) Peptidos de cdh3 y agentes que los comprenden
EA201491049A1 (ru) Противораковый слитый белок
EA201390820A1 (ru) Слитый белок против рака
SG178797A1 (en) Oligosaccharide chain added glp-1 peptide
NI201200134A (es) Polipéptidos agonistas que se enlazan a dr5
PE20130199A1 (es) Proteina de fusion robo1-fc y su utilizacion en el tratamiento de tumores

Legal Events

Date Code Title Description
FB Suspension of granting procedure